دورية أكاديمية
Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer
| العنوان: | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer |
|---|---|
| المؤلفون: | Kim, Chang Gon, Hong, Min Hee, Kim, Kyung Hwan, Seo, In-Ho, Ahn, Beung-Chul, Pyo, Kyoung-Ho, Synn, Chun-Bong, Yoon, Hong In, Shim, Hyo Sup, Lee, Yong Il, Choi, Seong Jin, Lee, Yun Jeong, Kim, Ellen Janine, Kim, Youngun, Kwak, Jeong-Eun, Jung, Jaehyung, Park, Su-Hyung, Paik, Soonmyung, Shin, Eui-Cheol, Kim, Hye Ryun |
| المساهمون: | Kim, Chang Gon, Hong, Min Hee, Kim, Kyung Hwan, Seo, In-Ho, Ahn, Beung-Chul, Pyo, Kyoung-Ho, Synn, Chun-Bong, Yoon, Hong In, Shim, Hyo Sup, Lee, Yong Il, Choi, Seong Jin, Lee, Yun Jeong, Kim, Ellen Janine, Kim, Youngun, Kwak, Jeong-Eun, Jung, Jaehyung, Park, Su-Hyung, Paik, Soonmyung, Shin, Eui-Cheol, Kim, Hye Ryun |
| بيانات النشر: | ELSEVIER SCI LTD |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Anti-programmed cell death-1 treatment, Non-small-cell lung cancer, CD8(+) T lymphocytes, Biomarker, T-CELLS, EXHAUSTION, SENESCENCE, DISEASE |
| الوصف: | Background: The predictive value of immune monitoring with circulating CD8(+) T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to investigate whether dynamic changes in PD-1(+) CD8(+) T lymphocytes have predictive value for durable clinical benefit (DCB) and survival after PD-1 blockade. Methods: Patients with recurrent and/or metastatic NSCLC treated with PD-1 inhibitors were enrolled (discovery cohort; n = 94). Peripheral blood was obtained immediately before and after one cycle of treatment with PD-1 blockade. Phenotyping of circulating CD8(+) T lymphocytes was conducted using multi-colour flow cytometry. Predictive values of dynamic changes in circulating PD-1(+) CD8(+) T lymphocytes during the first cycle were validated in an independent cohort (validation cohort; n = 54) of a prospective trial with a PD-1 inhibitor (NCT03486119). Results: Circulating PD-1(+) CD8(+) T lymphocytes were enriched with effector/memory populations with elevated expression of activation- and exhaustion-related markers. Reduction in the frequency of PD-1(+) cells among CD8(+) T lymphocytes after one cycle of treatment was associated with a higher probability of DCB and superior survival outcomes in the discovery cohort. Similar results were obtained in the analysis of tumour antigen NY-ESO-1-specific CD8(+) T lymphocytes and the validation cohort. Mechanistically, PD-1 molecule expression on CD8(+) T lymphocytes suppresses the effector functions of tumour antigen-specific CD8(+) T lymphocytes. Conclusions: Dynamic changes in circulating PD-1(+) CD8(+) T lymphocytes predict clinical, and survival benefit from PD-1 blockade treatment in NSCLC, providing a useful tool to identify patient subgroups who will optimally benefit from PD-1 inhibitors. (C) 2020 Elsevier Ltd. All rights reserved. ; 1 ; 1 ; N ; scie ; scopus |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0959-8049 1879-0852 |
| العلاقة: | EUROPEAN JOURNAL OF CANCER; J00809; Oncology; https://ir.ymlib.yonsei.ac.kr/handle/22282913/181873Test; 2-s2.0-85097453810; 000604902700016; T202101659; EUROPEAN JOURNAL OF CANCER, Vol.143 : 113-126, 2021-01; 67594 |
| DOI: | 10.1016/j.ejca.2020.10.028 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2020.10.028Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/181873Test |
| رقم الانضمام: | edsbas.A8029749 |
| قاعدة البيانات: | BASE |
| تدمد: | 09598049 18790852 |
|---|---|
| DOI: | 10.1016/j.ejca.2020.10.028 |